Galapagos’ R&D Roundtable showcases Toledo program - Seite 2

About the GLPG3970 clinical portfolio

CALOSOMA study: Phase 1 trial in psoriasis
The Calosoma Phase 1 trial (NCT04106297) is a double-blind, placebo-controlled study evaluating the safety, tolerability, PK and PD¹ of GLPG3970 single and multiple ascending doses in up to 52 adult healthy male subjects. GLPG3970 will now be investigated for 6 weeks in 25 subjects with moderate to severe psoriasis. The first patient was dosed recently.

SEA TURTLE study: Phase 2 trial in ulcerative colitis (UC)
This Phase 2 trial is a double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, PK and PD of GLPG3970 in up to 30 subjects with moderately to severely active UC. GLPG3970 or a placebo will be administered orally once daily for 6 weeks, with the primary endpoint of change from baseline in total Mayo Clinical Score (MCS).

LADYBUG study: Phase 2 trial in rheumatoid arthritis (RA)
This Phase 2 trial is a double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability, PK and PD of GLPG3970 in up to 25 participants with severely active RA and an inadequate response to methotrexate. GLPG3970 or a placebo will be administered orally once-daily for 6 weeks, with the primary endpoint of change from baseline of DAS28 CRP at week 6.

GLPG3970 is an investigational drug and its efficacy and safety have not been established.

For information about clinical trials with GLPG3970: www.clinicaltrials.gov.
For more information about the Toledo program: www.glpg.com/toledo-program

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises early discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
[phone]

Sofie Van Gijsel
Senior Director Investor Relations
[phone]
[e-mail]

Media:
Carmen Vroonen
Global Head of Communications & Public Affairs
[phone]

Anna Gibbins
Senior Director Therapeutic Areas Communications
[phone]
[e-mail]